发布于: 雪球转发:0回复:4喜欢:0

$药明康德(SH603259)$

Status and Outlook

There are two paths for a version of the BIOSECURE Act to progress through Congress: (1) as part of the FY25 NDAA or (2) attached to a larger legislative package this year. Notably, this legislative effort follows the same model that was used to target Chinese telecommunications companies in the late 2010s. Given the pace of movement, for stakeholders wishing to influence or amend the legislation, we recommend initiating outreach as soon as possible.
H.R. 7085 has been referred to the House Oversight and Accountability Committee and further action has not yet been announced. Although the China Select Committee does not have the ability to advance legislation, the Select Committee can build momentum for the bill. In addition, Rep. Gallagher also serves on the House Armed Services Committee, which allows him to include provisions in defense-related bills. We expect Rep. Gallagher to push for the inclusion of a potentially expanded version of the BIOSECURE Act in the FY25 National Defense Authorization Act as early as mid-April. Congressman Gallagher is not seeking reelection and may view this legislative effort as a legacy item.

Status and Outlook

There are two paths for a version of the BIOSECURE Act to progress through Congress: (1) as part of the FY25 NDAA or (2) attached to a larger legislative package this year. Notably, this legislative effort follows the same model that was used to target Chinese telecommunications companies in the late 2010s. Given the pace of movement, for stakeholders wishing to influence or amend the legislation, we recommend initiating outreach as soon as possible.
H.R. 7085 has been referred to the House Oversight and Accountability Committee and further action has not yet been announced. Although the China Select Committee does not have the ability to advance legislation, the Select Committee can build momentum for the bill. In addition, Rep. Gallagher also serves on the House Armed Services Committee, which allows him to include provisions in defense-related bills. We expect Rep. Gallagher to push for the inclusion of a potentially expanded version of the BIOSECURE Act in the FY25 National Defense Authorization Act as early as mid-April. Congressman Gallagher is not seeking reelection and may view this legislative effort as a legacy item.

全部讨论

04-18 13:43

研究生给大家翻译下:
《生物安全法案》版本在国会取得进展有两种途径:(1)作为25财年NDAA的一部分,或(2)附在今年更大的立法方案中。值得注意的是,这项立法工作遵循了2010年代后期针对中国电信公司的相同模式。鉴于行动的步伐,对于希望影响或修改立法的利益相关者,我们建议尽快启动外展活动。
H.R. 7085 已提交给众议院监督和问责委员会,尚未宣布进一步行动。尽管中国专责委员会没有能力推进立法,但专责委员会可以为该法案造势。此外,众议员加拉格尔还在众议院军事委员会任职,这使他能够在与国防相关的法案中加入条款。我们预计众议员加拉格尔最早将在 4 月中旬推动将《生物安全法》的潜在扩展版本纳入 FY25 国防授权法。国会议员加拉格尔不寻求连任,并可能将这项立法工作视为遗产项目。
那里是《生物安全法案》版本在国会取得进展的两条途径:(1)作为25财年NDAA的一部分,或(2)附在今年更大的立法方案中。值得注意的是,这项立法工作遵循了2010年代后期针对中国电信公司的相同模式。鉴于行动的步伐,对于希望影响或修改立法的利益相关者,我们建议尽快启动外展活动。
H.R. 7085 已提交给众议院监督和问责委员会,尚未宣布进一步行动。尽管中国专责委员会没有能力推进立法,但专责委员会可以为该法案造势。此外,众议员加拉格尔还在众议院军事委员会任职,这使他能够在与国防相关的法案中加入条款。我们预计众议员加拉格尔最早将在 4 月中旬推动将《生物安全法》的潜在扩展版本纳入 FY25 国防授权法。国会议员加拉格尔不寻求连任,并可能将这项立法工作视为遗产项目。

04-18 20:14

这是以前的吧

04-18 15:02

就是没进展…

04-18 13:51

啥意思啊